Involuntary movements, or dyskinesia, represent a debilitating complication of levodopa (L-
dopa) therapy for Parkinson's disease (PD). L-dopa-induced dyskinesia (LID) are ultimately …

Dopaminergic medications used in the treatment of patients with Parkinson's disease are
associated with motor and non-motor behavioural side-effects, such as dyskinesias and …

The phytocannabinoids of Cannabis sativa L. have, since ancient times, been proposed as a
pharmacological alternative for treating various central nervous system (CNS) disorders …

Lysosomal impairment causes lysosomal storage disorders (LSD) and is involved in
pathogenesis of neurodegenerative diseases, notably Parkinson disease (PD). Strategies …

L-3, 4-dihydroxyphenylalanine (L-DOPA) has been successfully used in the treatment of
Parkinson's disease (PD) for more than 50 years. It fulfilled the criteria to cross the blood …

Though a multi-facetted disorder, Parkinson's disease is prototypically characterized by
neurodegeneration of nigrostriatal dopaminergic neurons of the substantia nigra pars …

There is currently no cure for Parkinson's disease. The symptomatic therapeutic strategy
essentially relies on dopamine replacement whose efficacy was demonstrated more than 50 …

Abstract The 5-HT 2C receptor (R) displays a widespread distribution in the CNS and is
involved in the action of 5-HT in all brain areas. Knowledge of its functional role in the CNS …

The long-term replacement therapy with the dopamine (DA) precursor 3, 4-dihydroxy-l-
phenylalanine (L-DOPA) is a milestone in the treatment of Parkinson's disease (PD) …

Abstract L-DOPA-induced dyskinesia (LID) is the most common form of hyperkinetic
movement disorder resulting from altered information processing in the cortico-basal ganglia …